BioLine Rx (NASDAQ: BLRX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-17 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.150 | -0.100 | 0.0500 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of BioLine Rx (NASDAQ: BLRX) through any online brokerage.
Other companies in BioLine Rx’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), 89bio (NASDAQ:ETNB), Lumos Pharma (NASDAQ:LUMO), Aligos Therapeutics (NASDAQ:ALGS) and Infinity Pharmaceuticals (NASDAQ:INFI).
The latest price target for BioLine Rx (NASDAQ: BLRX) was reported by HC Wainwright & Co. on Tuesday, February 23, 2021. The analyst firm set a price target for 19.00 expecting BLRX to rise to within 12 months (a possible 1372.87% upside). 0 analyst firms have reported ratings in the last year.
The stock price for BioLine Rx (NASDAQ: BLRX) is $1.29 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for BioLine Rx.
BioLine Rx’s Q2 earnings are confirmed for Wednesday, August 17, 2022.
There is no upcoming split for BioLine Rx.
BioLine Rx is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.